Sicong Huang, Jiaqi Yang, Teng Xie, Yangwei Jiang, Yifan Hong, Xinyuan Liu, Xuyan He, Damiano Buratto, Dong Zhang, Ruhong Zhou, Tingbo Liang, Xueli Bai
The limited success of current targeted therapies for pancreatic cancer underscores an urgent demand for novel treatment modalities. The challenge in mitigating this malignancy can be attributed to the digestive organ expansion factor (DEF), a pivotal yet underexplored factor in pancreatic tumorigenesis. The study uses a blend of in vitro and in vivo approaches, complemented by the theoretical analyses, to propose DEF as a promising anti-tumor target. Analysis of clinical samples reveals that high expression of DEF is correlated with diminished survival in pancreatic cancer patients...
May 17, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)